TP53 and central nervous system cancer: The profiling of gliomas has revealed that the majority (~75%) of low-grade gliomas that carry IDH1 and TP53 mutations also harbor ATRX mutations, thus underscoring their crucial role in gliomagenesis, which has been indicated in the procession of impairing non-homologous end-joining DNA repair (84, 85).